Most biotech companies play at the cellular level. Pretzel Therapeutics? They’re untwisting mitochondrial dysfunction with the kind of precision that makes most molecular science look like finger painting.
In a space where rare disease funding feels more like a prayer than a pitch, Pretzel just pulled in fresh backing from The Mito Fund, the venture arm of the United Mitochondrial Disease Foundation. And while the amount is hush-hush, the signal is loud: If you’re working on POLG disorders or mtDNA depletion syndromes and your lead compound is already in Phase 1, the right people take notice.
Founded in 2019 by three heavyweights in mitochondrial biology, Claes Gustafsson, Michal Minczuk, and Nils-Göran Larsson, Pretzel was never about following the formula. This was science with intent. Precision over pretense. Add in Gabriel Martinez, Ph.D. (now Chief Scientific Officer) and the late Paul Thurk, Ph.D. (ARCH Venture Partners) as co-founders, and you’ve got a company built like a bioenergetic tank with a Nobel-caliber chassis.
And let’s be clear: this isn’t some one-patent, one-path play. Pretzel’s platform spans Genome Correction, Genome Expression Modulation, and Mitochondrial Quality Control. Translation: they aren’t just treating dysfunction, they’re engineering resilience.
At the top, Jay Parrish, Ph.D., Chairman and CEO (ex-Vir Bio), is steering this ship like a guy who’s seen biotech unicorns born in real time. Under his leadership, PX578, Pretzel’s first-in-class POLG activator, is now dosing healthy volunteers in a randomized Phase 1 study. The plan? Move fast into mitochondrial DNA depletion syndrome patients by 2026. And if you think that’s niche, think again. We’re talking a global population of ~33,000 with virtually no approved options.
The Mito Fund didn’t just write a check. They validated a vision, one backed by a scientific advisory board featuring Nobel winners like Sir John Walker and Roger Kornberg. That’s not window dressing. That’s architectural credibility.
Between their Waltham HQ and their Swedish R&D engine, Pretzel is running a cross-Atlantic model that fuses U.S. clinical scale with Nordic academic firepower. It’s lean, it’s strategic, and it’s deadly efficient.
